Track CAI International, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

CAI International, Inc. CAI · Stock Open CAI International, Inc. in new tab

23.04 USD
P/E
13.88
EPS
1.66
P/B
10.33
ROE
17.19
Target Price
34.23 USD
CAI International, Inc. logo

CAI International, Inc.

🧾 Earnings Recap – Q2 2026

Caris Life Sciences shares surged 24.2% following Q2 results as strong case volume growth and early enthusiasm for the Caris Detect multi-cancer early detection (MCED) test significantly exceeded investor expectations.

  • Total cases reached a record 59,200 in Q2, representing an 18% year-over-year increase, driven by both tissue and blood testing volumes.
  • Over 345,000 clinical oncology tests were performed, including more than 114,000 Whole Exome and Whole Transcriptome tests.
  • The proprietary database grew to over 1.13 million profiled patients, supporting Caris' AI-driven comprehensive molecular oncology platform.
  • Caris Detect MCED test drew physician and patient interest surpassing management’s own forecasts, with near-term demand potentially outpacing rollout capacity.
  • Expansion of the Precision Oncology Alliance added key members, strengthening commercial reach and collaborative research.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E13.88
EPS1.66
Book Value2.23
Price to Book10.33
Debt/Equity72.41
% Insiders48.920%
Growth
Revenue Growth0.27%
Earnings Growth-0.38%
Estimates
Forward P/E85.01
Forward EPS0.27
Target Mean Price34.23

DCF valuation

Model fair value for CAI International, Inc. (CAI)
Result
Sign in to run the valuation for CAI.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus Buy · mean target 34.23 USD (low 25.00, high 38.00) · as of 15 Nov 2026
Low 25.00
Mean 34.23
High 38.00
Price 23.04
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

CAI International, Inc. Logo CAI International, Inc. Analysis (CAI)

United States Industrials Official Website Stock

Is CAI International, Inc. a good investment? CAI International, Inc. (CAI) is currently trading at 23.04 USD. Market analysts have a consensus price target of 34.23 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 13.88. This relatively low multiple may signal that CAI International, Inc. is undervalued compared to historical market norms.

Earnings Schedule: CAI International, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 0.27.

Investor FAQ

Does CAI International, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is CAI International, Inc.?

CAI International, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 1.66.

Company Profile

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Exchange Ticker
NYQ (United States) CAI
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2021
0.90 USD
Sept. 27, 2021 0.3000
June 25, 2021 0.3000
March 25, 2021 0.3000
▸2020
0.50 USD
Dec. 24, 2020 0.2500
Sept. 25, 2020 0.2500
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion